Display options
Share it on

CNS Drugs. 2001;15(6):469-94. doi: 10.2165/00023210-200115060-00005.

Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective.

CNS drugs

H D Desai, J Seabolt, M W Jann

Affiliations

  1. Department of Pharmacy Practice and Pharmaceutical Sciences, Mercer University, Southern School of Pharmacy, Atlanta, Georgia 30341-4155, USA.

PMID: 11524025 DOI: 10.2165/00023210-200115060-00005

Abstract

Many psychiatric patients smoke, and are believed to be heavier smokers than those without psychiatric disorders. Cigarette smoking is one of the environmental factors that contributes to interindividual variations in response to an administered drug. Polycyclic aromatic hydrocarbons (PAHs) present in cigarette smoke induce hepatic aryl hydrocarbon hydroxylases, thereby increasing metabolic clearance of drugs that are substrates for these enzymes. PAHs have been shown to induce 3 hepatic cytochrome P450 (CYP) isozymes, primarily CYP1A1, 1A2 and 2E1. Drug therapy can also be affected pharmacodynamically by nicotine. The most common effect of smoking on drug disposition in humans is an increase in biotransformation rate, consistent with induction of drug-metabolising enzymes. Induction of hepatic enzymes has been shown to increase the metabolism and to decrease the plasma concentrations of imipramine, clomipramine, fluvoxamine and trazodone. The effect of smoking on the plasma concentrations of amitriptyline and nortriptyline is variable. Amfebutamone (bupropion) does not appear to be affected by cigarette smoking. Smoking is associated with increased clearance of tiotixene, fluphenazine, haloperidol and olanzapine. Plasma concentrations of chlorpromazine and clozapine are reduced by cigarette smoking. Clinically, reduced drowsiness in smokers receiving chlorpromazine, and benzodiazepines, compared with nonsmokers has been reported. Increased clearance of the benzodiazepines alprazolam, lorazepam, oxazepam, diazepam and demethyl-diazepam is found in cigarette smokers, whereas chlordiazepoxide does not appear to be affected by smoking. Carbamazepine appears to be minimally affected by cigarette smoke, perhaps because hepatic enzymes are already stimulated by its own autoinductive properties. Cigarette smoking can affect the pharmacokinetic and pharmacodynamic properties of many psychotropic drugs. Clinicians should consider smoking as an important factor in the disposition of these drugs.

References

  1. Neuropsychobiology. 1976;2(4):193-202 - PubMed
  2. Am J Psychiatry. 1990 Nov;147(11):1471-5 - PubMed
  3. J Clin Psychiatry. 1983 Nov;44(11):420-2 - PubMed
  4. Arch Gen Psychiatry. 1974 Aug;31(2):211-4 - PubMed
  5. Psychopharmacology (Berl). 1986;90(4):468-70 - PubMed
  6. Psychopharmacology (Berl). 1988;95(3):333-8 - PubMed
  7. J Int Med Res. 1980;8 Suppl 3:88-95 - PubMed
  8. J Clin Psychopharmacol. 1991 Oct;11(5):296-301 - PubMed
  9. Drug Metabol Drug Interact. 2000;16(1):15-38 - PubMed
  10. Psychiatry Res. 1989 May;28(2):153-9 - PubMed
  11. Drug Metab Rev. 1979;9(2):221-36 - PubMed
  12. Clin Pharmacol Ther. 1993 Mar;53(3):316-23 - PubMed
  13. Klin Wochenschr. 1986 Dec 1;64(23):1217-21 - PubMed
  14. Schizophr Res. 1997 Jan 17;23(1):55-60 - PubMed
  15. Clin Pharmacokinet. 1987 Apr;12(4):302-4 - PubMed
  16. Chest. 1985 Feb;87(2):223-6 - PubMed
  17. J Clin Psychopharmacol. 1989 Apr;9(2):98-104 - PubMed
  18. Cell Mol Neurobiol. 1988 Sep;8(3):285-91 - PubMed
  19. N Engl J Med. 1973 Feb 8;288(6):277-80 - PubMed
  20. Biol Psychiatry. 1997 Mar 15;41(6):717-23 - PubMed
  21. Br J Clin Pharmacol. 1996 Jun;41(6):605-8 - PubMed
  22. Pharmacotherapy. 1991;11(4):296-302 - PubMed
  23. Methods Find Exp Clin Pharmacol. 1983 Sep;5(7):479-87 - PubMed
  24. J Clin Invest. 1987 Nov;80(5):1466-71 - PubMed
  25. Am J Psychiatry. 1991 Jun;148(6):793-4 - PubMed
  26. Biol Psychiatry. 1987 Oct;22(10):1280-2 - PubMed
  27. Psychiatr Serv. 1995 May;46(5):435-6 - PubMed
  28. J Pharmacokinet Biopharm. 1992 Dec;20(6):591-609 - PubMed
  29. Pharmacol Ther. 1990;45(2):241-98 - PubMed
  30. Am J Psychiatry. 1981 Jun;138(6):841-2 - PubMed
  31. J Clin Psychopharmacol. 1993 Feb;13(1):46-51 - PubMed
  32. J Clin Pharmacol. 1997 Aug;37(8):737-43 - PubMed
  33. Schizophr Res. 1998 Sep 7;33(1-2):113-8 - PubMed
  34. Pharmacotherapy. 2000 Aug;20(8 Pt 2):139S-151S - PubMed
  35. Clin Pharmacokinet. 1993 Feb;24(2):161-76 - PubMed
  36. Ther Drug Monit. 1999 Feb;21(1):105-15 - PubMed
  37. N Engl J Med. 1979 Jan 25;300(4):199-200 - PubMed
  38. Clin Chem. 1988 May;34(5):863-80 - PubMed
  39. Eur J Clin Pharmacol. 1981;21(3):229-33 - PubMed
  40. Pharmacopsychiatry. 1994 Sep;27(5):210-1 - PubMed
  41. Schizophr Res. 1996 Nov 15;22(2):133-41 - PubMed
  42. Biol Psychiatry. 1991 Jul 15;30(2):109-15 - PubMed
  43. J Clin Psychopharmacol. 1993 Dec;13(6):383-90 - PubMed
  44. Int Clin Psychopharmacol. 1995 Sep;10(3):143-6 - PubMed
  45. Pharmacol Biochem Behav. 1991 Apr;38(4):875-80 - PubMed
  46. Biol Psychiatry. 1984 Aug;19(8):1265-8 - PubMed
  47. Psychopharmacology (Berl). 1996 Oct;127(4):311-4 - PubMed
  48. Clin Pharmacol Ther. 1977 Nov;22(5 Pt 2):749-56 - PubMed
  49. Psychopharmacology (Berl). 1983;80(1):14-8 - PubMed
  50. Int Clin Psychopharmacol. 1997 May;12(3):153-7 - PubMed
  51. Clin Pharmacokinet. 1996 Nov;31(5):372-85 - PubMed
  52. J Pharmacol Exp Ther. 1994 Jul;270(1):414-23 - PubMed
  53. Mol Psychiatry. 2000 Jul;5(4):410-7 - PubMed
  54. Trends Pharmacol Sci. 1992 Sep;13(9):346-52 - PubMed
  55. Clin Pharm. 1990 Feb;9(2):125-35 - PubMed
  56. Biol Psychiatry. 1985 Mar;20(3):329-32 - PubMed
  57. J Clin Invest. 1975 Feb;55(2):347-59 - PubMed
  58. Biochem Pharmacol. 1990 Oct 1;40(7):1427-32 - PubMed
  59. Clin Pharmacol Ther. 1977 Apr;21(4):453-6 - PubMed
  60. Clin Pharmacol Ther. 1980 Mar;27(3):301-12 - PubMed
  61. Science. 1972 Mar 17;175(4027):1248-50 - PubMed
  62. Br J Clin Pharmacol. 1999 Apr;47(4):445-9 - PubMed
  63. Clin Pharmacol Ther. 1979 Jul;26(1):103-13 - PubMed
  64. JAMA. 2000 Nov 22-29;284(20):2606-10 - PubMed
  65. Ther Drug Monit. 1986;8(3):279-84 - PubMed
  66. Neuropsychopharmacology. 1995 Jul;12(4):323-33 - PubMed
  67. Pharm Res. 1997 Mar;14(3):309-15 - PubMed
  68. Postgrad Med J. 1980;56 Suppl 1:99-102 - PubMed
  69. Br J Clin Pharmacol. 1987 Jun;23(6):759-63 - PubMed
  70. J Clin Psychopharmacol. 1987 Aug;7(4):222-9 - PubMed
  71. Eur J Clin Pharmacol. 1994;46(6):523-6 - PubMed
  72. Xenobiotica. 1998 Dec;28(12):1203-53 - PubMed
  73. J Clin Psychopharmacol. 1992 Apr;12(2):128-32 - PubMed
  74. Biol Psychiatry. 1990 Sep 15;28(6):529-31 - PubMed
  75. Clin Pharmacokinet. 1999 Jun;36(6):425-38 - PubMed
  76. Clin Pharmacol Ther. 1982 Apr;31(4):533-8 - PubMed
  77. Clin Pharmacokinet. 1989 Aug;17(2):90-108 - PubMed
  78. Clin Pharmacokinet. 1990 Sep;19(3):241-55 - PubMed
  79. J Clin Psychopharmacol. 1998 Feb;18(1):2-9 - PubMed
  80. Clin Pharmacokinet. 1999 Sep;37(3):177-93 - PubMed
  81. J Clin Pharmacol. 1999 Mar;39(3):252-9 - PubMed
  82. Clin Pharmacol Ther. 1995 Oct;58(4):399-403 - PubMed
  83. Br J Clin Pharmacol. 1994 Jan;37(1):71-4 - PubMed
  84. JAMA. 1977 Nov 14;238(20):2167-9 - PubMed

Substances

MeSH terms

Publication Types